Expanding the evidence for rivaroxaban in Atrial Fibrillation (AF) patients with comorbidites including Heart Failure (HF): from Randomized Controlled Trials (RCT) to Real World Evidence (RWE).

30 April 2017 (12:50 - 13:05)
Organised by:
Congress Presentation Part of: Management of co-morbidities in heart failure - Exploring new frontiers Atrial fibrillation (AF) HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure